How should baloxavir marboxil be dosed for acute uncomplicated influenza in patients ≥12 years (or children ≥5 years) based on weight, and what are its contraindications and alternative treatments?

Baloxavir Marboxil Dosing and Clinical Guidance

Baloxavir marboxil should be dosed as a single oral dose based on weight: 2 mg/kg for patients <20 kg, 40 mg for patients 20-79 kg, and 80 mg for patients ≥80 kg, administered within 48 hours of symptom onset for acute uncomplicated influenza. 1, 2

Weight-Based Dosing Algorithm

For patients ≥5 years of age with acute uncomplicated influenza:

• <20 kg: 2 mg/kg as single oral dose
• 20 to <80 kg: 40 mg as single oral dose
• ≥80 kg: 80 mg as single oral dose

1, 3, 2

The medication must be initiated within 2 days of illness onset for treatment efficacy. 1

Critical Administration Requirements

Do NOT administer baloxavir with:

• Dairy products
• Calcium-fortified beverages
• Polyvalent cation-containing laxatives or antacids
• Oral supplements containing calcium, iron, magnesium, selenium, or zinc

1, 3, 2

This restriction exists because polyvalent cations reduce baloxavir exposure by 48-63%, significantly compromising efficacy. 2

Absolute Contraindications and Restrictions

Baloxavir is NOT recommended for:

1. Severely immunocompromised patients as monotherapy (use oseltamivir instead) 1, 3
2. Pregnant women 1, 3, 2
3. Breastfeeding women 1, 3, 2

The pregnancy restriction stems from lack of human data, though animal studies showed no adverse effects at exposures 5-7 times the maximum recommended human dose. However, pregnant women are at higher risk for severe influenza complications, creating a clinical dilemma. 2

Preferred Alternative: Oseltamivir

When baloxavir is contraindicated, oseltamivir is the preferred alternative:

• Adults and adolescents ≥40 kg: 75 mg twice daily for 5 days
• Children 1-12 years: Weight-based dosing from 30-75 mg twice daily for 5 days
• Infants <12 months: 3.0 mg/kg twice daily for 5 days (per CDC/IDSA guidelines)

1, 3

Oseltamivir has the advantage of being FDA-approved for treatment in infants as young as 2 weeks and can be used in pregnancy, breastfeeding, and immunocompromised patients. 3

Pediatric Considerations

For children 5 to <12 years: Baloxavir is FDA-approved using the weight-based dosing above. Safety and efficacy data from the miniSTONE-2 trial showed comparable outcomes to oseltamivir with similar adverse event profiles (primarily gastrointestinal symptoms). 4

For children <5 years: Baloxavir is not FDA-approved for this age group in the U.S., though recent data in infants <1 year showed acceptable safety profiles. 5 Use oseltamivir as the preferred agent in this population.

Renal and Hepatic Impairment

No dose adjustment needed for:

• Mild to moderate hepatic impairment (Child-Pugh class B)
• Renal impairment with CrCl ≥50 mL/min

2

Severe renal or hepatic impairment has not been studied—use oseltamivir with appropriate renal dose adjustments in these cases. 1, 3

Post-Exposure Prophylaxis

Baloxavir can be used for post-exposure prophylaxis using the same single-dose, weight-based regimen as treatment, administered within 48 hours of exposure. 1, 3

However, oseltamivir remains the AAP's preferred agent for post-exposure prophylaxis, particularly in institutional outbreak settings. 1 Prophylaxis is not a substitute for vaccination and should not be used for routine or widespread prevention outside of outbreaks. 1

Common Pitfalls to Avoid

1. Timing error: Baloxavir must be given within 48 hours of symptom onset—efficacy beyond this window is not established
2. Drug interaction: Failing to separate baloxavir from polyvalent cations by several hours drastically reduces drug levels
3. Immunocompromised patients: Using baloxavir monotherapy in severely immunocompromised patients risks treatment failure and resistance emergence
4. Resistance emergence: Polymerase acidic protein variants with reduced susceptibility emerged in 9.7% of baloxavir recipients in phase 3 trials 6, though clinical significance remains unclear

Efficacy Data

In high-risk patients (CAPSTONE-2 trial), baloxavir reduced median time to symptom improvement by 29.1 hours compared to placebo (73.2 vs 102.3 hours, p<0.0001). 7 Time to symptom alleviation was similar between baloxavir and oseltamivir, but baloxavir achieved greater viral load reduction at 24 hours. 7, 6

The single-dose convenience of baloxavir offers a significant adherence advantage over 5-day oseltamivir therapy, particularly valuable in outpatient settings and pediatric populations. 4